Oragenics INC S-1 registration statements

Oragenics, Inc. has filed an amendment to its registration statement to facilitate a new securities offering, aiming to raise at least $15 million in gross proceeds to address its immediate liquidity needs and mitigate substantial doubt about its ability to continue as a going concern beyond Q3 2025.

Oragenics, Inc. is seeking to raise up to $20 million through an offering of Series H Preferred Stock and Warrants to fund its ONP-002 concussion clinical trials and address significant financial challenges, including an auditor's going concern doubt and NYSE American listing non-compliance.

Oragenics is launching a public offering of up to 15,151,515 units to fund the development of its ONP-002 drug for mild traumatic brain injury.

Oragenics, Inc. is conducting a public offering of up to 15,151,515 units to fund the development of its ONP-002 concussion treatment and for general corporate purposes.

Oragenics, Inc. is launching a public offering of up to 15,151,515 units to raise capital for its ONP-002 concussion treatment and other corporate purposes.

Oragenics, Inc. announces a public offering of common stock and pre-funded warrants to raise up to $5 million for its ONP-002 concussion treatment and general corporate purposes.

Oragenics, Inc. announces a public offering of common stock and pre-funded warrants to raise up to $5 million for the development of its ONP-002 concussion treatment and for general corporate purposes.